Department of Pharmaceutics, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , 110016 Liaoning , PR China.
Department of Pharmacy , The First Affiliated Hospital of China Medical University , Shenyang , 110016 Liaoning , PR China.
Mol Pharm. 2018 Jul 2;15(7):2870-2882. doi: 10.1021/acs.molpharmaceut.8b00357. Epub 2018 Jun 13.
In this work, a nano-in-micro carrier was constructed by loading polymer-lipid hybrid nanoparticles (NPs) into porous and hollow yeast cell wall microparticles (YPs) for macrophage-targeted oral delivery of cabazitaxel (CTX). The YPs, primarily composed of natural β-1,3-d-glucan, can be recognized by the apical membrane receptor, dectin-1, which has a high expression on macrophages and intestinal M cells. By combining electrostatic force-driven self-deposition with solvent hydration/lyophilization methods, the positively charged NPs loaded with CTX or fluorescence probes were efficiently packaged into YPs, as verified by scanning electron microscope (SEM), atomic force mircoscope (AFM), and confocal laser scanning microscopy (CLSM) images. NP-loaded YPs (NYPs) showed a slower in vitro drug release and higher drug stability compared with NPs in a simulated gastrointestinal environment. Biodistribution experiments confirmed a widespread distribution and extended retention time of NYPs in the intestinal tract after oral administration. Importantly, a large amount of NYPs were primarily accumulated and transported in the intestinal Peyer's patches as visualized in distribution and absorption site studies, implying that NYPs were mainly absorbed through the lymphatic pathway. In vitro cell evaluation further demonstrated that NYPs were rapidly and efficiently taken up by macrophages via receptor dectin-1-mediated endocytosis using a mouse macrophage RAW 264.7 cell line. As expected, in the study of in vivo pharmacokinetics, the oral bioavailability of CTX was improved to 32.1% when loaded in NYPs, which is approximately 5.7 times higher than that of the CTX solution, indicating the NYPs are efficient for oral targeted delivery. Hence, this nano-in-micro carrier is believed to become a hopeful alternative strategy for increasing the oral absorption of small molecule drugs.
在这项工作中,通过将聚合物-脂质杂化纳米颗粒(NPs)装载到多孔和中空酵母细胞壁微颗粒(YPs)中,构建了一种纳米-微载体,用于卡巴他赛(CTX)的巨噬细胞靶向口服递药。YPs 主要由天然β-1,3-d-葡聚糖组成,可被巨噬细胞和肠 M 细胞上高表达的顶端膜受体 dectin-1 识别。通过静电驱动力驱动的自沉积与溶剂水合/冻干方法相结合,将负载 CTX 或荧光探针的带正电荷的 NPs 有效地包装到 YPs 中,这通过扫描电子显微镜(SEM)、原子力显微镜(AFM)和共聚焦激光扫描显微镜(CLSM)图像得到了验证。负载 NP 的 YPs(NYPs)在模拟胃肠道环境中表现出比 NPs 更慢的体外药物释放和更高的药物稳定性。体内分布实验证实,口服给药后 NYPs 在肠道中分布广泛且保留时间延长。重要的是,在分布和吸收部位研究中,大量的 NYPs 主要在肠道派尔集合淋巴结中积累和运输,这表明 NYPs 主要通过淋巴途径吸收。体外细胞评估进一步表明,NYPs 通过小鼠巨噬细胞 RAW 264.7 细胞系中受体 dectin-1 介导的内吞作用被巨噬细胞快速有效地摄取。不出所料,在体内药代动力学研究中,当负载在 NYPs 中时,CTX 的口服生物利用度提高到 32.1%,约为 CTX 溶液的 5.7 倍,表明 NYPs 是一种有效的口服靶向递药系统。因此,这种纳米-微载体有望成为提高小分子药物口服吸收的有前途的替代策略。